Generic Invokana Availability
Last updated on May 9, 2024.
Invokana is a brand name of canagliflozin, approved by the FDA in the following formulation(s):
INVOKANA (canagliflozin - tablet;oral)
-
Manufacturer: JANSSEN PHARMS
Approval date: March 29, 2013
Strength(s): 100MG [RLD], 300MG [RLD]
Has a generic version of Invokana been approved?
No. There is currently no therapeutically equivalent version of Invokana available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Invokana. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical formulations
Patent 10,617,668
Issued: April 14, 2020
Inventor(s): Wang Wenhua & Outwin Todd & Joseph Thomas C.
Assignee(s): Janssen Pharmaceutica NVThe present invention relates to formulations including compounds of Formula (I),
Patent expiration dates:
- May 11, 2031✓✓
- May 11, 2031✓✓
- May 11, 2031✓✓
- May 11, 2031✓✓
- May 11, 2031✓✓
- May 11, 2031✓✓
- May 11, 2031✓✓
- May 11, 2031✓✓
- May 11, 2031✓✓
- May 11, 2031
-
Patent 7,943,582
Patent expiration dates:
- February 26, 2029✓✓✓
- February 26, 2029✓✓✓
- February 26, 2029✓✓✓
- February 26, 2029
-
Patent 7,943,788
Patent expiration dates:
- July 14, 2027✓✓
- July 14, 2027
-
Glucopyranoside compound
Patent 8,222,219
Issued: July 17, 2012
Inventor(s): Nomura Sumihiro & Kawanishi Eiji & Ueta Kiichiro
Assignee(s): Mitsubishi Tanabe Pharma CorporationA compound of the formula:
Patent expiration dates:
- April 11, 2025✓
- April 11, 2025✓
- April 11, 2025✓
- April 11, 2025
-
Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Patent 8,513,202
Issued: August 20, 2013
Inventor(s): Nomura Sumihiro & Kawanishi Eiji
Assignee(s): Mitsubishi Tanabe Pharma CorporationA novel crystal form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.
Patent expiration dates:
- December 3, 2027✓✓✓
- December 3, 2027✓✓✓
- December 3, 2027✓✓✓
- December 3, 2027
More about Invokana (canagliflozin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (257)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: SGLT-2 inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.